



Anzu-cel for People With Advanced Melanoma | Presented at ASCO 2026



Melanoma is a type of cancer that can happen in cells that make pigments, such as those found in the skin and eye.

In people with advanced melanoma, their cancer may return often, and they may not live long.



Anzutresgene autoleucel (anzu-cel) is a type of anticancer cellular therapy that binds to a specific marker on the surface of cancer cells, including melanoma. The marker is made up of 2 parts called PRAME and HLA.



In the clinical trial called IMA203-101, 33 people with melanoma received anzu-cel.



Researchers followed people in the study for a median (middle value) of **18.7 months** after they received anzu-cel.

How well does anzu-cel work?



56% of the people with melanoma had their cancer go away partially or completely.



Anzu-cel helped shrink or eliminate melanoma tumors in many parts of the body where the cancer had spread.




The treatment worked for a **median of 14.6 months** in people with melanoma; **46% were alive at 2 years**.


Anzu-cel worked in many people for a long time

How safe is anzu-cel?

Researchers assessed safety by looking at how many people had side effects like **CRS** and **ICANS**.



CRS involves a person's immune system. Everyone in the study got CRS. Most people (**82%**) had mild CRS. Some people (**18%**) had severe CRS.



ICANS affects the brain. Most people did not get ICANS. Some people (**12%**) had mild ICANS. Few people (**6%**) had severe ICANS.


Side effects of anzu-cel were predictable and manageable

How did people's cancer return?

In 73% of people who received anzu-cel, their melanoma came back or got worse.



In 50% of people, 1 organ was involved. In 25% of people, 2 organs were involved. In 25% of people, ≥ 3 organs were involved.



33% of people only had tumor growth. 42% of people only got new tumors. 25% of people had tumor growth and new tumors.

If the cancer returned, it was usually localized

In another clinical trial called SUPRAME, researchers are looking at how well anzu-cel works and how safe it is compared with other treatments in people with advanced melanoma. Results from the SUPRAME trial will help the FDA decide whether to approve anzu-cel for people with advanced melanoma.